Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Immvira Bioscience Files for Hong Kong IPO to Advance Novel Oncolytic Immunotherapy and Engineered Exosome Pipeline

Fineline Cube Jul 17, 2026
Company Deals

Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression

Fineline Cube Jul 17, 2026
Company Deals

Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline

Fineline Cube Jul 17, 2026
Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

Allergan Aesthetics Secures European Commission Approval for Boey (trenibotulinumtoxinE) – First Rapid-Onset, Short-Duration Botulinum Neurotoxin Serotype E for Glabellar Lines

Fineline Cube Jul 20, 2026
Company Drug

GSK Reports Mixed Phase III Results for Camlipixant in Refractory Chronic Cough: CALM-1 Trial Meets Primary Endpoint While CALM-2 Falls Short

Fineline Cube Jul 20, 2026
Company Drug

Hybio Pharmaceutical’s Semaglutide Clinical Trial Filing Accepted by China’s NMPA

Fineline Cube Sep 12, 2023

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced that the National Medical Products Administration...

Company Deals

Hasten Biopharmaceutical Secures Licensing Deal for LIB’s Lerodalcibep in Greater China

Fineline Cube Sep 12, 2023

China-based Hasten Biopharmaceutical Co., Ltd has entered into a licensing agreement with US firm LIB...

Company Drug

FDA Extends Pfizer’s Comirnaty Vaccine Indication for Omicron XBB.1.5 Variant

Fineline Cube Sep 12, 2023

The US Food and Drug Administration (FDA) has granted Pfizer (NYSE: PFE) an indication extension...

Company Drug

Amgen’s Lumakras Combo Shows Promising Results in KRAS-mutated NSCLC Early-Stage Trial

Fineline Cube Sep 12, 2023

Amgen (NASDAQ: AMGN) has announced positive early-stage data for its KRASG12C inhibitor Lumakras (sotorasib) when...

Company Drug

Gilead’s Trodelvy Combo with MSD’s Keytruda Shows Promise in NSCLC Phase II Trial

Fineline Cube Sep 12, 2023

Gilead (NASDAQ: GILD) has announced interim data from a Phase II trial assessing the antibody-drug...

Company Deals

Wecare Medical Secures Pre-Series A Funding to Advance Brain Health Technology

Fineline Cube Sep 12, 2023

Hangzhou-based Wecare Medical, a developer of brain disease diagnosis, monitoring, and treatment products, has reportedly...

Company Deals

Sandoz Inks Deal with Samsung Bioepis for Ustekinumab Biosimilar SB17

Fineline Cube Sep 12, 2023

The Sandoz (SWX: SDZ) unit of Switzerland-based Novartis (NYSE: NVS) has announced the in-licensing of...

Policy / Regulatory

China Updates Narcotics and Psychotropic Substances Catalog, Adds Three Substances

Fineline Cube Sep 12, 2023

The National Medical Products Administration (NMPA), Ministry of Public Security, and National Health Commission have...

Company Drug

Sinovac Biotech Advances SA55 COVID-19 Neutralizing Antibody into Phase II Trials

Fineline Cube Sep 12, 2023

China-based vaccines firm Sinovac Biotech Ltd (NASDAQ: SVA) has announced the completion of a Phase...

Company Deals

Shanghai Haoyuan Chemexpress Aims to Raise RMB 1.16 Billion with Convertible Bonds

Fineline Cube Sep 12, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Shanghai Haoyuan Chemexpress Co., Ltd (SHA: 688131) has...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for HRS-7450 Acute Ischemic Stroke Study

Fineline Cube Sep 12, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Drug

SinoMab BioScience Receives NMPA Approval for Phase I Study of Atopic Dermatitis Drug SM17

Fineline Cube Sep 12, 2023

Hong Kong-based biotechnology company SinoMab BioScience Ltd (HKG: 3681) has received approval from the National...

Company

Merck & Co. Becomes First Multinational to Register Unit in Hainan’s Lecheng Pilot Zone

Fineline Cube Sep 12, 2023

US pharmaceutical major Merck, Sharp & Dohme Inc., (MSD, NYSE: MRK) has officially registered a...

Company Drug

Haisco Pharmaceutical Gets NMPA Approval for HSK21542 Chronic Pruritus Clinical Study

Fineline Cube Sep 12, 2023

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received approval...

Company Drug

ImmuneOnco’s IMM2510 and IMM27M Achieve Milestones in Phase I Clinical Trials

Fineline Cube Sep 12, 2023

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced the completion of patient enrollment for...

Company Drug

CDE Indicates BTD Status for Visirna’s VSA001, Sperogenix’s Vamorolone, and Zai Lab’s Efgartigimod

Fineline Cube Sep 11, 2023

The Center for Drug Evaluation (CDE) website has indicated that Visirna Therapeutics’ novel siRNA therapy...

Company Deals

Shanghai Junshi Biosciences to Acquire Stake in Anlingke Biopharmaceutical for Cancer Therapy Programs

Fineline Cube Sep 11, 2023

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced its intention to...

Company Deals

Broncus Medical Inc. to Acquire Fibernova Holding Corporation for USD 2.7 Million

Fineline Cube Sep 11, 2023

Broncus Medical Inc., (HKG: 2216) a provider of lung disease precision intervention solutions with operations...

Company Medical Device

Lepu Medical Technology Receives NMPA Approval for MemoSorb Biodegradable PFO Occluder

Fineline Cube Sep 11, 2023

China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has announced...

Company Deals

EA Pharma and TransThera Sciences Collaborate on GI and Liver Disease Therapies

Fineline Cube Sep 11, 2023

Japan-based EA Pharma Co., Ltd and China-headquartered TransThera Sciences (Nanjing) Inc. have jointly announced the...

Posts pagination

1 … 505 506 507 … 696

Recent updates

  • Allergan Aesthetics Secures European Commission Approval for Boey (trenibotulinumtoxinE) – First Rapid-Onset, Short-Duration Botulinum Neurotoxin Serotype E for Glabellar Lines
  • GSK Reports Mixed Phase III Results for Camlipixant in Refractory Chronic Cough: CALM-1 Trial Meets Primary Endpoint While CALM-2 Falls Short
  • Wepon Medical Secures FDA Clinical Approval for WP107 (Huperzine A Oral Solution) in Healthy Volunteers Following NMPA Clearance for Myasthenia Gravis
  • Jacobio Launches Phase Ib/III Trial of Pan-KRAS Inhibitor JAB-23E73 for KRAS-Mutated Pancreatic Cancer in Partnership with AstraZeneca
  • CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Allergan Aesthetics Secures European Commission Approval for Boey (trenibotulinumtoxinE) – First Rapid-Onset, Short-Duration Botulinum Neurotoxin Serotype E for Glabellar Lines

Company Drug

GSK Reports Mixed Phase III Results for Camlipixant in Refractory Chronic Cough: CALM-1 Trial Meets Primary Endpoint While CALM-2 Falls Short

Company Drug

Wepon Medical Secures FDA Clinical Approval for WP107 (Huperzine A Oral Solution) in Healthy Volunteers Following NMPA Clearance for Myasthenia Gravis

Company Drug

Jacobio Launches Phase Ib/III Trial of Pan-KRAS Inhibitor JAB-23E73 for KRAS-Mutated Pancreatic Cancer in Partnership with AstraZeneca

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.